Related Experiment Video
Updated: Mar 21, 2026
06:17
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
22.9K
Optimized polypeptide for a subunit vaccine against avian reovirus
Dana Goldenberg1, Avishai Lublin2, Ezra Rosenbluth2
1Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel; Migal - Galilee Technology Center, Kiryat Shmona, Israel.
Vaccine
|May 8, 2016
Summary
A specific fragment of Avian reovirus (ARV) Sigma C protein, residues 122-326, shows promise for a new recombinant subunit vaccine. This fragment elicits stronger neutralizing antibodies against ARV infection than full-length protein or other fragments.
Area of Science:
- Veterinary Virology
- Molecular Immunology
- Vaccine Development
Background:
- Avian reovirus (ARV) causes disease, necessitating genotype-specific vaccines.
- Rapidly mutating ARV strains challenge traditional vaccine approaches.
- Recombinant subunit vaccines offer adaptability to emerging viral strains.
Purpose of the Study:
- To identify the immunogenic region of ARV Sigma C (SC) protein for vaccine development.
- To evaluate the efficacy of different SC protein fragments in inducing neutralizing antibodies.
Main Methods:
- Production of full-length and truncated ARV SC protein fragments in E. coli.
- Immunization with SC fragments and assessment of antibody levels and neutralizing activity.
- Comparison of immune responses induced by fragments versus whole virus vaccine.
Main Results:
- The SC fragment (residues 122-326) induced significantly higher levels of anti-ARV antibodies.
- Antibodies generated against the 122-326 fragment showed superior neutralization of ARV embryo infection.
- This fragment likely presents key epitopes effectively, excluding potential suppressor sequences.
Conclusions:
- The ARV SC protein fragment spanning residues 122-326 is a strong candidate for a recombinant subunit vaccine.
- This approach allows for rapid adaptation to new ARV genetic variants.
- Further development could lead to a more effective and adaptable ARV vaccine.
